Stada Gears Up For Higher-Strength Adalimumab As Alvotech Clears Up Legal Overhang
Iceandic Firm Has Settled European IP Disputes With Originator AbbVie
Executive Summary
Alvotech and its strategic partner Stada are preparing to launch their higher-strength adalimumab candidate AVT02 in Europe after settling intellectual property disputes with originator AbbVie.